About US
Contact us
-
With FTC eyeing biopharma M&A deals, Pfizer refiles paperwork for $43B buyout of SeagenAn FTC lawsuit aimed atblockingAmgen’s $27.8 billion buyout of Horizon Therapeutics has raised concerns that the United States’ antitrust watchdog is tightening the screws on major M&A moves in t2023/6/13
-
Sanofi goes 'all in' on AI with new app to support company's manufacturing, R&D and moreSanofi is jumping on the artificial intelligence boat with a new app and a pledge to become “the first pharma company powered by artificial intelligence at scale.” The app, called plai and develop2023/6/13
-
FDA sets the stage for adcomm on Sanofi, AZ's RSV prospect later this weekAs GSK and Pfizer look to roll out their adultrespiratory syncytial virus (RSV) vaccines later this year, Sanofi and AstraZeneca hope to join them on the market with an antibody designed to protect i2023/6/8
-
Novo Holdings, Gurnet Point team up to buy antibiotics maker Paratek for $462MNovo Holdings and Gurnet Point have added antibiotics maker Paratek Pharma to their fold in a biopharma M&A deal worth approximately $462 million. The two investment firms willsnap up2023/6/8
-
After Merck's flashpoint IRA lawsuit, Biogen CEO and others register their own complaintsMerck has taken the lead, filing a lawsuit seeking to overturn drug pricing measures in the Inflation Reduction Act (IRA). Now, emboldened by the New Jersey drugmaker, the leaders of other companies2023/6/6
-
GSK's adult RSV shot Arexvy nabs European approval weeks after US endorsementAfter GSK nabbed a coveted world-first approval for its adult respiratory syncytial virus (RSV) vaccine in the U.S., it has scoredthe same title in Europe withArexvy. Theauthorizationcovers adults2023/6/6
-
Amgen extends restraining order in Horizon pursuit as court's scheduling comes into focusWhen Amgenrevealed its intention to buy Horizon Therapeutics in 2022's largest biopharma buyout, executives with the California-based drugmakersaidthey hoped to close the deal in the first half of 202023/6/1
-
ASCO: Merck's Keytruda trips in EGFR lung cancer as Roche's Tecentriq fails in kidney cancerThe PD-1/L1 inhibitor class of drugs has vastly improved care for many patients with cancer, but some meds in the class have posted trial failures lately. At the American Society of Clinical Oncology2023/6/1
-
After breakup with Otsuka, Akebia finds new partner for oral anemia drug in EuropeAkebia Therapeutics has found a new partner in Europe for oral anemia drug Vafseo in chronic kidney disease. But the deal is smaller than the company's prior pact with Otsuka. Medice Arzn2023/5/29
-
Johnson & Johnson takes another step in CAR-T race with Bristol Myers in multiple myelomaIn a race with Bristol Myers Squibb to advance cell therapies to treat patients at an earlier stage of multiple myeloma, Johnson & Johnson has hit another milepost. J&J and co-dev2023/5/29